PHILADELPHIA--(BUSINESS WIRE)--iECURE, a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced that it has expanded its management team with the appointment of David Garrett as chief financial officer. In addition, the company has added two experienced industry executives into key roles in the organization. Kim Smith will serve as vice president of finance, and Ashley Kim will serve as director of business development.
“We are moving aggressively to add experienced biotech executives to support our existing pipeline of therapeutic candidates as well as identify additional opportunities for in-licensing new delivery technologies,” said Joseph Truitt, chief executive officer of iECURE. “David’s financial leadership will add a critical component to our management team which will position us well for both near- and long-term execution of our portfolio plans. Kim and Ashley have significant experience in their areas of expertise and will help to fortify our efforts as well. We are pleased to welcome David, Kim and Ashley to the team.”
Mr. Garrett joins iECURE from Dynacure, where he served as chief financial officer and managed a successful Series C raise of €58 million and led its IPO process. Previously, he held various roles at Nabriva Therapeutics, including vice president, corporate controller and head of investor relations and senior director, business planning and analysis. At Nabriva, Mr. Garrett led all Wall Street-facing activities, completed over $150 million in equity capital raises and oversaw all SEC reporting and compliance functions. Mr. Garrett was also responsible for leading Nabriva’s redomicile from Austria to Ireland. Prior to Nabriva, Mr. Garrett held senior-level finance roles at Covis Pharmaceuticals, Auxilium Pharmaceuticals and ViroPharma and was a manager at KPMG. Mr. Garrett received an MBA and B.S. in accountancy from Villanova University and is a certified public accountant in Pennsylvania.
Ms. Smith joins iECURE from Genova Group, an accounting advisory firm where she served as managing director. Before that, she was vice president of finance and corporate controller for Tmunity Therapeutics. Previously, she served in financial leadership positions at biotechnology companies Fibrocell and ViroPharma. She earned a B.S. in accounting from Lehigh University and is a certified public accountant.
Ms. Kim joins iECURE from Jaguar Gene Therapy, a Deerfield portfolio company, where she served as director of business development and corporate strategy, leading business development efforts including sourcing new business opportunities, conducting due diligence and working with legal counsel on licensing agreements and term sheets. Prior to joining Jaguar, she worked as a genetics analyst at Deerfield Management Company, where she identified the lead program for Jaguar Gene Therapy. She received a M.S. in biotechnology from Johns Hopkins University and a B.A. in psychology from Queens College.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with significant unmet need. We are advancing our pipeline in close partnership with the world-class translational engine at the University of Pennsylvania’s Gene Therapy Program. Using in vivo editing, our methods focus on inserting functional genes into patients’ genomes, offering long-term, stable expression of those genes. With our team’s proven track record, as well as the University of Pennsylvania’s deep expertise and translational genetic medicine engine, we believe reversing the course of these devastating diseases is now within reach. For more information, visit www.iecure.com and follow on LinkedIn.